Lawsuit claims Sanofi dragged its feet on Lemtrada OK to avoid rights payoff

Sanofi ($SNY) is accused of stalling its multiple sclerosis drug Lemtrada to avoid paying out $708 million to rights holders as required by its 2011 deal to buy Genzyme. As part of that deal, the French drugmaker agreed to a series of milestone payments, including an FDA approval deadline for Lemtrada. A lawsuit filed on behalf of rights holders claims Sanofi deliberately filed a substandard approval application to delay the FDA nod. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.